Semaglutide: A Promising Treatment for MASH

Overview of Semaglutide

Semaglutide, a weight-loss and diabetes medication, is gaining attention for its potential in treating metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. Marketed under the names Ozempic, Wegovy, and Rybelsus, this once-weekly injection could represent a significant breakthrough for MASH, a serious and progressive liver disease.

Research Findings

Published in April 2025 in the New England Journal of Medicine, a study conducted by an international team of metabolic specialists suggests that semaglutide may be the first drug-based therapy for MASH. Currently, MASH lacks approved pharmacological treatments, despite its associations with liver failure and cancer. The phase 3 clinical trial results indicate that nearly 63% of participants experienced reduced inflammation, while approximately 37% showed improvements in liver scarring.

Understanding MASH: The Rising Silent Liver Disease

What is MASH?

MASH, previously known as non-alcoholic steatohepatitis (NASH), is an increasingly prevalent liver disease characterized by fat accumulation, leading to liver swelling and scarring. If left untreated, this condition can severely impair liver function. MASH shares common risk factors with obesity and type 2 diabetes, and current treatment protocols primarily focus on lifestyle modifications aimed at weight loss.

Challenges in Treatment

For many individuals, lifestyle changes alone do not suffice. This dilemma has inspired international research collaborations like the ESSENCE project, which aims to identify more effective treatments for MASH. Researchers are investigating whether semaglutide can alleviate liver fat and promote healing, based on its established efficacy in weight loss for type 2 diabetes patients.

Clinical Trial Methodology

Study Design

A randomized, double-blind, placebo-controlled trial was conducted across 22 countries to evaluate the efficacy of semaglutide in treating MASH. This rigorous study design allows for a direct comparison between groups receiving the treatment and those receiving a placebo.

Participants and Dosing

Approximately 1,200 individuals with moderate to severe liver scarring participated in the study, which is scheduled to last for 240 weeks. Participants were randomly assigned to receive either weekly semaglutide injections or a placebo. The standard dose of 2.4 mg was used, consistent with weight loss prescriptions, to assess its effects on liver health.

Data Collection

Liver biopsies were taken at the beginning of the trial, at week 72, and again at 240 weeks to evaluate changes in liver tissue. The research aimed to determine whether semaglutide could reduce inflammation without increasing liver scarring and improve scarring without exacerbating inflammation.

Results After 72 Weeks

Weight Loss and Liver Health Improvements

After 72 weeks, the interim analysis revealed significant differences between the two groups. Participants receiving semaglutide lost an average of 10.5% of their body weight, compared to just 2% in the placebo group. Notably, 483 out of the 768 individuals on semaglutide showed reduced liver fat accumulation and inflammation without additional scarring. Furthermore, 283 participants experienced a decrease in liver scarring.

Overall Health Benefits

Participants not only improved their liver health but also experienced overall health benefits associated with semaglutide’s effects on diabetes and weight management. While some mild side effects, such as nausea, were reported, the treatment was generally well tolerated.

Future Implications of Semaglutide in MASH Treatment

Long-Term Study Goals

The ongoing study will continue to track long-term effects, including the sustainability of liver health improvements and the potential for semaglutide to prevent progression to cirrhosis or liver failure. Early results have garnered attention, with Dr. Philip Newsome, a lead investigator and liver specialist, calling the findings a “major breakthrough” that could transform MASH treatment approaches.

Conclusion

While it may take time before semaglutide can be prescribed specifically for MASH, individuals currently using the drug may find additional health benefits, alleviating some concerns associated with their condition.

References

Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V. (2025). Phase 3 Trial of Semaglutide in Metabolic Dysfunction—Associated Steatohepatitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2413258
News Details. Novo Nordisk. Accessed June 5, 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html